Emerging trends in pharmaceutical marketing
Download
1 / 18

Emerging Trends in Pharmaceutical Marketing - PowerPoint PPT Presentation


  • 131 Views
  • Uploaded on

Emerging Trends in Pharmaceutical Marketing. Pricing Strategy Workshop. Some History…. The ODB froze the 1993/94 formulary prices Québec and Saskatchewan have policies where they need to have the best available price Resulted in almost no drug price inflation until 2003. But….

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about ' Emerging Trends in Pharmaceutical Marketing' - drake


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript

Some history
Some History…

  • The ODB froze the 1993/94 formulary prices

  • Québec and Saskatchewan have policies where they need to have the best available price

  • Resulted in almost no drug price inflation until 2003


But…

  • Price difference between U.S. is increasing

  • Cross-border shopping has become a sizeable problem

  • Manufacturers are looking for solutions


Prices canada vs international
PricesCanada vs. International

Canadian prices are lower

Prices at par

Canadian prices are higher

Source: Annual Report, CEPMB, 1999-2004


Prices canada vs international1
PricesCanada vs. International

Canadian prices are lower

Prices at par

Canadian prices are higher

Source: Annual Report, PMPRB, 1999-2004


Prices canada vs international2
PricesCanada vs. International

Canadian prices are lower

Stronger currencies

Prices at par

Canadian prices are higher

Source: Annual Report, PMPRB, 1999-2004


Prices canada vs international3
PricesCanada vs. International

Canadian prices are lower

Weaker USD

Prices at par

Canadian prices are higher

Source: Annual Report, PMPRB, 1999-2004


Prices canada vs international4
PricesCanada vs. International

  • When compared to the U.S., U.K. and Switzerland, Canadian prices (patented drugs) are lower

  • Affected by exchange rates – lower Canadian dollar since 2002 (36-month average) is reversing trends

  • The difference with the U.S. is increasing

Increasing Internet sales

Pressures to reduce the difference


Prices canada vs international5
PricesCanada vs. International

New Products Launched:

  • Prices “at par” internationally

    Existing Products:

  • Price increases

    • Restricted by the PMPRB – bending the rules

    • Restricted by the provinces

?


Formulary increases by provinces
Formulary IncreasesBy provinces


Formulary increases and timing by provinces botox unit dose vial
Formulary Increases and TimingBy provinces, BOTOX (UNIT DOSE VIAL)

April 2004




Are formularies the last answer
Are formularies the last answer?

  • Private Drug Plans are ±40% of the National drug market

  • Only few have managed formularies

  • Most are price takers, even with adjudication system


Price increases private data 2003 2004
Price Increases – Private Data2003-2004

  • Sample of 1200 DINs (72% of all Ontario private drug plan claims – July 2005)

    • Approximately 200 price increases on brand products form Jan. 2002 to July 2005

    • Approximately 25 price increases on generic products form Jan. 2002 to July 2005

    • 30 manufacturers

  • Most increases

    • 3%-6% (brand products)

    • 2% to 300% (generic products)


Brogan price index private drug plans
Brogan Price IndexPrivate Drug Plans

January 2002 = 1


Brogan price index versus inflation
Brogan Price IndexVersus Inflation

June 2003 = 1


Price increases conclusions
Price Increases – Conclusions

  • Depends on who is paying

  • Timing is everything – especially when the PMPRB is concerned

  • What is the reaction of all stakeholders?


ad